A phase I trial of JD5037 to treat nonalcoholic steatohepatitis (NASH)

Trial Profile

A phase I trial of JD5037 to treat nonalcoholic steatohepatitis (NASH)

Planning
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2017

At a glance

  • Drugs JD 5037 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Dec 2017 New trial record
    • 14 Dec 2017 According to a Jenrin Discovery media release, the US FDA has cleared the Investigational New Drug (IND) Application for JD5037.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top